According to the New York Times, the a treatment in clinical trials from Osiris, which used adult stem cells was no more effective, over all, than a placebo in treating a life-threatening complication of bone marrow transplantation, though certain patients seemed to be helped.
This is a major set back for the company producing the stem-cell treatment, as they hoped that it would be the first stem cell product approved by the FDA. Read the full article here.
About:
The Partnerships in Clinical Trials Blog focuses optimization intelligence, regulatory trends and globalization strategies for both as sponsors and CROs. It is an extension of the Partnerships in Clinical Trials Conference.
As a reader of the Partnerships in Clinical Trials blog, mention code XP1718BLOG when registering to join us in Sao Paulo for Partnerships in Clinical Trials Latin America to receive a discount of $100 off the current rate!
Would you like to guest blog on our site? Or send us feedback? Send an email to jpereira@iirusa.com.



.gif)
0 comments:
Post a Comment